Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the country. Now, another pharma major is reportedly reassessing how it views investments there. Pfizer CEO Albert Bourla has shared his qualms about the German government’s policy proposals in a letter to Chancellor Friedrich Merz, according to reports. German newspaper Handelsblatt was the first to report the news of the letter.